The abstract is read at the publisher; the summary is JClub's.
Relcobatinib (ELVN-001) shows marked selectivity for BCR::ABL1 and robust anti-tumor activity in a human CML mouse xenograft model as monotherapy and with asciminib.
- Why it matters: Chronic myeloid leukemia treatment needs BCR::ABL1 inhibition while avoiding off-target kinase effects that contribute to toxicity seen with other TKIs.
- What they did: The study assessed kinase selectivity versus off-target kinases, tested in vitro activity against native BCR::ABL1 and clinically relevant TKI-resistant mutants, and evaluated efficacy in a BCR::ABL1 mouse xenograft model alone and combined with asciminib.
- The result: Relcobatinib’s selective targeting and strong activity in vitro, plus durable tumor regression in combination with asciminib, support its potential to improve efficacy and tolerability for CML and other BCR::ABL1-driven malignancies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.